[Lung cancer - on the way to a molecular classification].
Treatment options for patients with advanced lung cancer have greatly improved in recent years. New molecular-targeted drugs are avaliable based on predictive biomarkers. Molecular diagnostics are key to successful therapy. Guidelines and recommendations for lung cancer testing and treatment are evolving, and it is increasingly challenging to stay up-to-date. In view of the rapid development in the lung cancer field, the current article discusses the current evidence for lung cancer classification and testing, and illustrates new perspectives in modern oncology.